Ticker
ACAD

Price
18.57
Stock movement down
-0.09 (-0.48%)
Company name
ACADIA Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
3.01B
Ent værdi
3.03B
Pris/omsætning
5.88
Pris/bog
7.06
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-15.32%
3 års afkast
-23.54%
5 års afkast
-9.55%
10 års afkast
12.21%
Senest opdateret: 2023-01-27

UDBYTTE

ACAD betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning5.88
Pris til egenkapital7.06
EV i forhold til salg5.92

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier161.93M
EPS (TTM)-1.34
FCF pr. aktie (TTM)-0.70

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)511.50M
Bruttofortjeneste (TTM)501.19M
Driftsindkomst (TTM)-222.19M
Nettoindkomst (TTM)-217.34M
EPS (TTM)-1.34
EPS (1 år frem)-0.78

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)97.98%
Driftsmargin (TTM)-43.44%
Fortjenstmargin (TTM)-42.49%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter154.84M
Nettotilgodehavender56.14M
Omsætningsaktiver i alt521.55M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver602.49M
Kreditor10.01M
Kortfristet/nuværende langsigtet gæld63.00M
Summen af kortfristede forpligtelser116.57M
Sum gæld176.81M
Aktionærernes egenkapital425.69M
Materielle nettoaktiver425.69M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-113.30M
Investeringsudgifter (TTM)1.00K
Fri pengestrøm (TTM)-113.30M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-51.06%
Afkast af aktiver-36.07%
Afkast af investeret kapital-49.97%
Kontant afkast af investeret kapital-26.05%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning18.57
Daglig høj18.77
Daglig lav18.39
Daglig volumen921K
Højeste gennem alle tider57.00
1 års analytiker estimat18.47
Beta0.59
EPS (TTM)-1.34
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation27 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACADS&P500
Nuværende prisfald fra top notering-67.42%-15.08%
Højeste prisfald-96.29%-56.47%
Højeste efterår dato12 Nov 20109 Mar 2009
Gennemsnitlig fald fra toppen-47.90%-11.49%
Gennemsnitlig tid til nyt højdepunkt51 days13 days
Maks. tid til nyt højdepunkt1820 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ACAD (ACADIA Pharmaceuticals Inc) company logo
Markedsværdi
3.01B
Markedsværdi kategori
Mid-cap
Beskrivelse
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Personale
510
Investor relationer
-
SEC-indsendelser
Adm. direktør
Stephen R. Davis
Land
USA
By
San Diego
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
SAN DIEGO, January 09, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. ...
9. januar 2023
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
3. januar 2023
SAN DIEGO, January 03, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in p...
3. januar 2023
Acadia Pharmaceuticals is working to develop novel RNA-based medicines for the treatment of severe and rare genetic diseases of the central nervous system. The On-Balance-Volume (OBV) line has weake...
3. januar 2023
SAN DIEGO, December 21, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00...
21. december 2022
SAN DIEGO, November 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
8. november 2022
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
3. november 2022
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2. november 2022
SAN DIEGO, November 02, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
2. november 2022
Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
1. november 2022
Næste side